Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05401656
Other study ID # 77454
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 30, 2022
Est. completion date May 29, 2023

Study information

Verified date May 2022
Source Murdoch Childrens Research Institute
Contact Lane Collier
Phone 0383416200
Email acor@mcri.edu.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective study in paediatric, adolescent and young adult patients aged 7 to 18 years to validate the use of the Apple Watch's electrocardiogram (ECG) function in measuring QT prolongation during and or after cancer therapy.


Description:

A prospective study in paediatric, adolescent and young adult patients aged 7 to 18 years to validate the use of the Apple Watch's ECG function in measuring QT prolongation during and or after cancer therapy. Primary Objective: To evaluate the agreement between QTc measured using 12 lead ECG and Apple Watch using mean absolute error calculations. Secondary Objectives: 1. To calculate the sensitivity and specificity for measuring prolonged QTc using the Apple Watch. 2. To calculate the interobserver variability between the two health care professional readings of QTc. Rationale: Leveraging existing wearable technology for monitoring of QTc prolongation has the ability to scale routine screening strategies across large populations, and can facilitate ambulatory care. Utilising the Apple iWatch to monitor QTc prolongation in this study improves patient outcomes by facilitating real-time monitoring of potential irregularities, widespread screening, detection, and quicker initiation of treatment solutions.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date May 29, 2023
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group 7 Years to 18 Years
Eligibility Inclusion Criteria: - Paediatric or Adolescent diagnosis of cancer AND an inpatient of The Royal Children's Hospital, Melbourne at the time of consent. - Patient Age = 7 years at time of eligibility screening - If Age < 18 years, parent or guardian able to provide consent - Parental or participant ( if > 18 years of age) possession of the following at time of eligibility screening, ascertained from automatic hardware/software/device pairing check: - iPhone (5s or later) with iOS version 11.0 or later defined as iPhone model/iOS version used to complete screening eligibility. - Apple Watch (Series 1 or later) with watchOS version 4.0 or later defined as Apple Watch model/watchOS paired with iPhone used to complete screening eligibility. Apple Watch will be provided as part of the study. - Proficient in written and spoken English, defined by self-report of comfort reading, writing, and speaking English on iPhone. - Valid phone number associated with iPhone, ascertained from self-report. - Valid email address, ascertained from self-report. Exclusion Criteria: - Less than 7 years of age and unable to wear Apple Watch - Older than 18 years of age without guardian or parent to provide consent - Interpreter required for consent purposes

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ECG application
The app together with the device (Apple Watch) will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
12 lead ECG
The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as Apple Watch ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.

Locations

Country Name City State
Australia The Royal Children's Hospital Parkville Victoria

Sponsors (1)

Lead Sponsor Collaborator
Murdoch Childrens Research Institute

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recording of a 12 lead ECG and Apple Watch ECG 12 lead ECG and Apple Watch ECG recordings of QT interval will be taken at the time point of care.The Apple iWatch ECG app will be placed on the left wrist to record a V1 (lead I) ECG and on the left ankle to record a V2 (lead II) ECG reading from which the QT interval can be calculated. Day 1 of inpatient stay
Primary Recording of a 12 lead ECG and Apple Watch ECG 12 lead ECG and Apple Watch ECG recordings of QT interval will be taken at the time point of care.The Apple iWatch ECG app will be placed on the left wrist to record a V1 (lead I) ECG and on the left ankle to record a V2 (lead II) ECG reading from which the QT interval can be calculated. Day 4 of inpatient stay
Primary Calculation of QT interval by two blinded health professionals The Apple iWatch ECG and 12 lead ECG will be de-identified and given appropriate study numbers. This data will be listed separately for each patient. The QT interval for each recording will be calculated. This is the time corresponding to beginning of depolarization to repolarization of the ventricles. It is calculated using a standardised approach (Fridericia's formula:QTcF = QT divided by cube root of RR). Day 1 of inpatient stay
Primary Calculation of QT interval by two blinded health professionals The Apple iWatch ECG and 12 lead ECG will be de-identified and given appropriate study numbers. This data will be listed separately for each patient. The QT interval for each recording will be calculated. This is the time corresponding to beginning of depolarization to repolarization of the ventricles. It is calculated using a standardised approach (Fridericia's formula:QTcF = QT divided by cube root of RR). Day 4 of inpatient stay
Primary Mean and Median QTc measurement using Apple iWatch ECG The mean and median QTc will be calculated separately for Day 1 and Day 4 Day 1 and Day 4 of inpatient stay
Primary Mean and Median QTc measurement using 12 lead ECG The mean and median QTc will be calculated separately for Day 1 and Day 4 Day 1 and Day 4 of inpatient stay
Secondary Abnormal QTc that is greater than 0.48mm on 12 lead ECG and Apple Watch ECG From the analysis of QT measurements from Outcome 2, prolonged or abnormal QTc measurement will be noted. An abnormal QTc is greater than 0.48mm. This data will be collected separately for each patient. Day 1 and day 4 of inpatient stay
Secondary Sensitivity calculations of Apple Watch vs 12 Lead ECG Sensitivity is calculated only in the participants who are declared to have QTc prolongation (abnormal QTc) and is calculated as the proportion patients with QTc prolongation on the Apple Watch among those with QTc prolongation on the 12-lead ECG. Day 1 and day 4 of inpatient stay
Secondary Specificity calculations of Apple Watch vs 12 Lead ECG Specificity is calculated only in participants who do not have QTc prolongation and is calculated as the proportion patients who do not have QTc prolongation on the Apple Watch among those who do not have QTc prolongation on the 12-lead ECG. Day 1 and day 4 of inpatient stay
Secondary To calculate the interobserver variability between the two health care professional readings of QTc. The corrected QT interval will be calculated on both Apple Watch ECG and the 12 lead ECG for each patient and measured by a health professional. QT interval will be calculated by the health professional by using the QT and RR interval from the ECGs using Frederichias interval (QTcF = QT divided by cube root of RR). This data will be collected separately for each patient for each patient The standard deviation of the difference in QTc interval between the two observers will be reported. Day 1 and day 4 of inpatient stay
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab